DLBCL

Kami J. Maddocks, MD, professor of clinical internal medicine in the Division of Hematology at The Ohio State University Wexner Medical Center, spoke with The American Journal of Managed Care® (AJMC®) about treatment approaches for diffuse large B-cell lymphoma (DLBCL).

Julio Chavez, MD, MS, of Moffitt Cancer Center, spoke with The American Journal of Managed Care® (AJMC®) about how new approvals will alter decision making in the treatment of diffuse large B-cell lymphoma (DLBCL).

Andrew Zelenetz, MD, PhD, medical oncologist at Memorial Sloan Kettering Cancer Center, is the current chair of the Non-Hodgkin Lymphoma Guidelines panel of the National Comprehensive Cancer Network (NCCN).

Facilitating access to treatments for diffuse large B-cell lymphoma (DLBCL) remains a top issue.

Nearly 5 years after approval of the first CAR T-cell therapy, treatment is moving into second line, and patients have more options than ever for diffuse large B-cell lymphoma. How do physicians choose? Bita Fakhri, MD, MPH, hematologist-oncologist at the University of California San Francisco, discusses the process.